Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Wellcome Relenza

Executive Summary

"Dear Healthcare Professional" letter sent July 10 to highlight addition of bolded warning to zanamivir labeling. The warning addresses events of bronchospasm and decline in lung function reported in some patients, and advises against Relenza administration to patients with underlying airway disease such as asthma or chronic obstructive pulmonary disease (1"The Pink Sheet" Jan. 31, p. 20). A new patient information leaflet has been developed, and a second "Dear Healthcare Professional" letter will be mailed at the beginning of the flu season in the fall

You may also be interested in...



Relenza Dear Doctor Letter In EU Follows U.S. Advisory

Glaxo Wellcome is warning European prescribers about potential side effects with Relenza one week after similar concerns were raised by FDA.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS036341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel